The narrative spans four generations, highlighting the hereditary nature of breast cancer and its impact on family dynamics.

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

Carle Health and OSF HealthCare are working to bring lifesaving screening to the uninsured and the underinsured. As part of ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

Liverpool ONE will bring all things fantastic and frightful at the Halloween Street Party this October, including a ...

Smoking is a bad habit yes but there are too many smokers who ignore the health warning. We bring to you this list of 11 ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Dr. Kurdi received his Medical Degree with honors from The Faculty of Medicine of Damascus University. Dr. Kurdi also completed his residency at St. Joseph Mercy Hospital, Oakland, MI, a fellowship in ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...